RxDoctor Payments Data

Jim Li, DO

Family Medicine · Flushing, NYNPI 1053394106

Payments from drug & device makers

$18,395in general payments, 2019–2025

Across 524 payments — averaging $35.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$2K
  • AstraZeneca$2K
  • Novo Nordisk$1K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • plus $10K from 37 others

What the payments were for

  • Consulting fees$8004%
  • Speaking & faculty fees$4202%
  • Food & beverage$17,13393%
  • Education$420%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,395 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$25,326
Medicare patients
37
Services billed
311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AbrysvoRsv Vacc, Pref A And Pref B/Pf1,643$496,686
ShingrixVaricella-Zoster Ge/As01b/Pf1,675$351,176
JardianceEmpagliflozin65$73,288
ArexvyRsvpref3 Antigen/As01e/Pf241$69,977
JanuviaSitagliptin Phosphate48$57,366
VascepaIcosapent Ethyl121$49,716
MounjaroTirzepatide15$35,049
OzempicSemaglutide24$26,422
Boostrix TdapDiphth,pertuss(Acell),tet Vac379$24,478
EliquisApixaban22$21,020
Diclofenac Epolamine44$19,229
ProliaDenosumab11$18,874
TrulicityDulaglutide11$18,152
MresviaRsv Vaccine, Pref, Mrna/Pf54$15,666
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$13,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerAbrysvo, Eliquis$287$517,7071,665 claims
GSKShingrix, Arexvy$812$421,1541,916 claims
Boehringer IngelheimJardiance, Tradjenta$284$86,25376 claims
MerckJanuvia$895$57,36648 claims
Lilly USA, LLCMounjaro, Trulicity$1,332$53,20126 claims
Novo NordiskOzempic, Rybelsus$1,401$38,47537 claims
AmgenProlia$741$18,87411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.

Other family medicine in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →